Detalhe da pesquisa
1.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lancet
; 403(10432): 1141-1152, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461841
2.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Lancet
; 403(10432): 1153-1163, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461843
3.
Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor Therapies.
Retina
; 41(4): 669-670, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33165295
4.
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.
Pharmaceut Med
; 38(1): 63-73, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049618
5.
Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022.
Clin Ophthalmol
; 17: 385-390, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726365
6.
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.
Pharmaceut Med
; 33(3): 219-233, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31933286
7.
Thyroid hormone and heart failure.
Curr Heart Fail Rep
; 3(3): 114-9, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16914103